Antibody-Mediated Protection against Respiratory Viral Infection

ABSTRACT

Effective antibody responses are critical for protection against many human pathogens, including those with tropism for the respiratory tract (RT). Systemic immunoglobulin (Ig)G responses as well as mucosal IgA responses play complementary roles in protection against RT infections, and induction of a tissue-specific, isotype-appropriate humoral response is central to successful vaccination strategies. For respiratory virus infections in which current vaccines are either not available or not fully effective, antibody-mediated therapies may provide a viable treatment option. Prophylactic administration of polyclonal or monoclonal antibodies shows the best clinical efficacy, whereas therapeutic administration of antibodies after infection can also be highly protective but is greatly dependent on timing; efficacy declines soon after onset of disease symptoms. Further understanding of the mechanisms underlying antibody-mediated protection against respiratory virus infections may lead to improved immunization strategies as well as more effective antibody-based therapeutics.

KEYWORDS

Respiratory virus - antibody-mediated therapy - monoclonal antibody - vaccine - respiratory - virus - host defenses

REFERENCES

• 1 Whitton J L, Slifka M K, Liu F et al.. The regulation and maturation of antiviral immune responses.  Adv Virus Res. 2004;  63 181-238
• 2 Slifka M K, Hanifin J M. Smallpox: the basics.  Dermatol Clin. 2004;  22 263-274 vi
• 3 Epstein S L, Lo C Y, Misplon J A et al.. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice.  J Immunol. 1997;  158 1222-1230
• 4 Edghill-Smith Y, Bray M, Whitehouse C A et al.. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.  J Infect Dis. 2005;  191 372-381
• 5 Bouvet J P, Fischetti V A. Diversity of antibody-mediated immunity at the mucosal barrier.  Infect Immun. 1999;  67 2687-2691
• 6 Holmgren J, Czerkinsky C. Mucosal immunity and vaccines.  Nat Med. 2005;  11(Suppl 4) S45-S53
• 7 Slifka M K, Ahmed R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity.  Trends Microbiol. 1996;  4 394-400
• 8 Franklin E C. Structure and function of immunoglobulins.  Acta Endocrinol Suppl(Copenh). 1975;  194 77-95
• 9 Stockwin L H, Holmes S. Antibodies as therapeutic agents: vive la renaissance!.  Expert Opin Biol Ther. 2003;  3 1133-1152
• 10 Burton D R. Opinion: antibodies, viruses and vaccines.  Nat Rev Immunol. 2002;  2 706-713
• 11 Griffin D, Levine B, Tyor W et al.. The role of antibody in recovery from alphavirus encephalitis.  Immunol Rev. 1997;  159 155-161
• 12 Fujioka H, Emancipator S N, Aikawa M et al.. Immunocytochemical colocalization of specific immunoglobulin A with Sendai virus protein in infected polarized epithelium.  J Exp Med. 1998;  188 1223-1229
• 13 Mazanec M B, Coudret C L, Fletcher D R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies.  J Virol. 1995;  69 1339-1343
• 14 Bomsel M, Heyman M, Hocini H et al.. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM.  Immunity. 1998;  9 277-287
• 15 Kato H, Kato R, Fujihashi K, McGhee J R. Role of mucosal antibodies in viral infections.  Curr Top Microbiol Immunol. 2001;  260 201-228
• 16 Schmaljohn A L, Johnson E D, Dalrymple J M, Cole G A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis.  Nature. 1982;  297 70-72
• 17 Gould E A, Buckley A, Barrett A D, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice.  J Gen Virol. 1986;  67(Pt 3) 591-595
• 18 Cox R J, Brokstad K A, Ogra P. Influenza virus: immunity and vaccination strategies: comparison of the immune response to inactivated and live, attenuated influenza vaccines.  Scand J Immunol. 2004;  59 1-15
• 19 Tamura S, Iwasaki T, Thompson A H et al.. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection.  J Gen Virol. 1998;  79(Pt 2) 291-299
• 20 Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa.  Jpn J Infect Dis. 2004;  57 236-247
• 21 Renegar K B, Small Jr P A, Boykins L G, Wright P F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract.  J Immunol. 2004;  173 1978-1986
• 22 Fenner F, Henderson D A, Arita I et al.. Smallpox and Its Eradication: The Pathogenesis, Immunology, and Pathology of Smallpox and Vaccinia. Geneva; World Health Organization 1988
• 23 Hammarlund E, Lewis M W, Hansen S G et al.. Duration of antiviral immunity after smallpox vaccination.  Nat Med. 2003;  9 1131-1137
• 24 Crotty S, Felgner P, Davies H et al.. Cutting edge: long-term B cell memory in humans after smallpox vaccination.  J Immunol. 2003;  171 4969-4973
• 25 CDC . Impact of vaccines universally recommended for children: United States, 1990-1998.  MMWR Morb Mortal Wkly Rep. 1999;  48 243-248
• 26 Amanna I, Slifka M K. Public fear of vaccination: separating fact from fiction.  Viral Immunol. 2005;  18 307-315
• 27 Christie C D, Marx M L, Daniels J A, Adcock M P. Pertussis containment in schools and day care centers during the Cincinnati epidemic of 1993.  Am J Public Health. 1997;  87 460-462
• 28 Kim H W, Canchola J G, Brandt C D et al.. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.  Am J Epidemiol. 1969;  89 422-434
• 29 Chin J, Magoffin R L, Shearer L A et al.. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.  Am J Epidemiol. 1969;  89 449-463
• 30 Fulginiti V A, Eller J J, Sieber O F et al.. Respiratory virus immunization, I: A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.  Am J Epidemiol. 1969;  89 435-448
• 31 Kapikian A Z, Mitchell R H, Chanock R M et al.. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.  Am J Epidemiol. 1969;  89 405-421
• 32 Chihrin S, Loutfy M R. Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.  Expert Rev Anti Infect Ther. 2005;  3 251-262
• 33 Wesselhoeft C. Treatment of scarlet fever and diphtheria.  Med Clin North Am. 1936;  19 1389-1407
• 34 Skerrett S J. Antibody treatment of lower respiratory tract infections.  Semin Respir Infect. 2001;  16 67-75
• 35 Zeitlin L, Cone R A, Moench T R, Whaley K J. Preventing infectious disease with passive immunization.  Microbes Infect. 2000;  2 701-708
• 36 Casadevall A. Passive antibody therapies: progress and continuing challenges.  Clin Immunol. 1999;  93 5-15
• 37 Casadevall A. Antibody-based therapies for emerging infectious diseases.  Emerg Infect Dis. 1996;  2 200-208
• 38 Casadevall A, Scharff M D. Return to the past: the case for antibody-based therapies in infectious diseases.  Clin Infect Dis. 1995;  21 150-161
• 39 Sawyer L A. Antibodies for the prevention and treatment of viral diseases.  Antiviral Res. 2000;  47 57-77
• 40 Dunman P M, Nesin M. Passive immunization as prophylaxis: when and where will this work?.  Curr Opin Pharmacol. 2003;  3 486-496
• 41 Liu W, Zou P, Chen Y H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.  Immunol Lett. 2004;  93 131-136
• 42 Traggiai E, Becker S, Subbarao K et al.. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.  Nat Med. 2004;  10 871-875
• 43 Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus.  Rev Med Virol. 2004;  14 149-168
• 44 Hwang W Y, Foote J. Immunogenicity of engineered antibodies.  Methods. 2005;  36 3-10
• 45 Peterson N C. Advances in monoclonal antibody technology: genetic engineering of mice, cells, and immunoglobulins.  ILAR J. 2005;  46 314-319
• 46 AmericanAcademyofPediatrics . Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.  Pediatrics. 2003;  112(6 Pt 1) 1442-1446
• 47 DeVincenzo J P, Hall C B, Kimberlin D W et al.. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.  J Infect Dis. 2004;  190 975-978
• 48 Zhao X, Chen F P, Sullender W M. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.  Virology. 2004;  318 608-612
• 49 Zhao X, Chen F P, Megaw A G, Sullender W M. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.  J Infect Dis. 2004;  190 1941-1946
• 50 Yang Z Y, Werner H C, Kong W P et al.. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.  Proc Natl Acad Sci U S A. 2005;  102 797-801
• 51 Lang A B, Cryz Jr S J, Schurch U et al.. Immunotherapy with human monoclonal antibodies: fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin.  J Immunol. 1993;  151 466-472
• 52 Cheng Y, Wong R, Soo Y O et al.. Use of convalescent plasma therapy in SARS patients in Hong Kong.  Eur J Clin Microbiol Infect Dis. 2005;  24 44-46
• 53 Keller M A, Stiehm E R. Passive immunity in prevention and treatment of infectious diseases.  Clin Microbiol Rev. 2000;  13 602-614
• 54 Harrison L H, Halsey N A, McKee Jr K T et al.. Clinical case definitions for Argentine hemorrhagic fever.  Clin Infect Dis. 1999;  28 1091-1094
• 55 Enria D A, Barrera Oro J G. Junin virus vaccines.  Curr Top Microbiol Immunol. 2002;  263 239-261
• 56 Patel T B, Naidu B PB. Smallpox and sulphonamide.  Indian Med Gaz. 1940;  75 730-732
• 57 Couzi G, Kircher J P. Immunotherapie de la Variole.  Bulletin de l'Institut d'hygiene du Maroc. 1941;  1 59-68